AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31145817 — intervention group
Group type: COMPARATOR
Intervention: Synthetic simulated umbilical cord task trainer (ART)
Number of subjects: 27
Study 28892645 — intervention group
Group type: EXPERIMENTAL
Intervention: P11-4 + fluoride varnish
Number of subjects: 0
Study 28892645 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish alone
Number of subjects: 0
Study 27291387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with fractional CO2 laser, targeted UVB phototherapy, and topical 0.05% clobetasol propionate cream
Number of subjects: 14
Study 27291387 — intervention group
Group type: COMPARATOR
Intervention: Targeted UVB phototherapy and topical 0.05% clobetasol propionate cream
Number of subjects: 14
Study 24479388 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-supplemented food service concept
Number of subjects: 84
Study 24479388 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital menu
Number of subjects: 84
Study 22704766 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-balloon catheter
Number of subjects: 210
Study 22704766 — intervention group
Group type: COMPARATOR
Intervention: PGE2 vaginal insert
Number of subjects: 210
Study 20413054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-directed intervention (six-contact, eight-week)
Number of subjects: 437
Study 20413054 — intervention group
Group type: COMPARATOR
Intervention: Automated telephone symptom management intervention
Number of subjects: 437
Study 17664919 — intervention group
Group type: EXPERIMENTAL
Intervention: 27G x 35 mm standard needle with internal caliber of 0.215 mm
Number of subjects: 266
Study 17664919 — intervention group
Group type: COMPARATOR
Intervention: 27G x 35 mm XL Monoprotect needle with internal caliber of 0.265 mm
Number of subjects: 266
Study 16269974 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/day)
Number of subjects: 132
Study 16269974 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg/day)
Number of subjects: 132
Study 16269974 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 132
Study 16269974 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 132
Study 11983186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (dose stratified from 1.25 mg to 40 mg per day)
Number of subjects: 51
Study 11983186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11983186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (dose response)
Number of subjects: 51
Study 10071830 — intervention group
Group type: EXPERIMENTAL
Intervention: Normaten FC (generic atenolol)
Number of subjects: 12
Study 10071830 — intervention group
Group type: COMPARATOR
Intervention: Tenormin (innovator atenolol)
Number of subjects: 12
Study 10071830 — intervention group
Group type: EXPERIMENTAL
Intervention: Normaten FC
Number of subjects: 12
Study 10071830 — intervention group
Group type: COMPARATOR
Intervention: Tenormin
Number of subjects: 12
Study 10071830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 12
Study 7747370 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha and vinblastine (VBL)
Number of subjects: 41
Study 7747370 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 41
Study 1771902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IgIV) (0.4 g/kg during 5 consecutive days, total dose of 2.0 g/kg)
Number of subjects: 150
Study 1771902 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 150
Study 1771902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IgIV)
Number of subjects: 150
Study 6460558 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 89
Study 6460558 — intervention group
Group type: COMPARATOR
Intervention: carbenicillin
Number of subjects: 89
Study 31779620 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training for patients and their social support providers (n=423) in a randomized controlled study.
Number of subjects: 563
Study 31779620 — intervention group
Group type: EXPERIMENTAL
Intervention: App supporting communication between staff, patients, and their social support providers (n=423) in a case-control study.
Number of subjects: 563
Study 31779620 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for staff (n=140) tested in a pre-experimental study with a pre/post-design.
Number of subjects: 563
Study 31779620 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication interventions including an app.
Number of subjects: 563
Study 31779620 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation outcomes including pAEs, patient/treatment satisfaction, work satisfaction, safety culture, training-related outcomes.
Number of subjects: 563
Study 29855317 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills building education and multiple micronutrient supplementation provided bi-monthly from preconception, twice-weekly during preconception, daily during pregnancy, and daily for 6 months post-partum.
Number of subjects: 0
Study 29855317 — intervention group
Group type: COMPARATOR
Intervention: Standard of care including non-regulated community-based health sessions and daily iron and folic acid supplementation during pregnancy.
Number of subjects: 0
Study 29855317 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills building education and multiple micronutrient supplementation.
Number of subjects: 0
Study 27237018 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powder (MNP) daily in complementary feeding for 2 months
Number of subjects: 240
Study 27237018 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) without MNP
Number of subjects: 240
Study 27237018 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powder (MNP)
Number of subjects: 240
Study 24577485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose edoxaban
Number of subjects: 0
Study 24577485 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 0
Study 24577485 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran 150 mg bid
Number of subjects: 0
Study 24577485 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 0
Study 24577485 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose edoxaban
Number of subjects: 0
Study 24577485 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran 110 mg bid
Number of subjects: 0
Study 24577485 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran 150 mg bid and Rivaroxaban
Number of subjects: 0
Study 22236802 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 173
Study 22236802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 20818821 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth pectin quadruple therapy (20 mg rabeprazole bid, 1000 mg amoxicillin bid, 100 mg bismuth pectin qid, and 500 mg levofloxacin qd)
Number of subjects: 215
Study 20818821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (20 mg omeprazole bid, 1000 mg amoxicillin bid for 5 d, followed by 20 mg omeprazole bid, 500 mg tinidazole bid, 500 mg clarithromycin bid for another 5 d)
Number of subjects: 215
Study 20818821 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (20 mg omeprazole bid, 1000 mg amoxicillin bid, 500 mg clarithromycin bid)
Number of subjects: 215
Study 17192116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-based coaching programme (3 contacts with pharmacist, mean duration 13-20 minutes)
Number of subjects: 151
Study 17192116 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study 15193180 — intervention group
Group type: EXPERIMENTAL
Intervention: vax‐SPIRAL vaccine
Number of subjects: 101832
Study 15193180 — intervention group
Group type: COMPARATOR
Intervention: Heberbiovac‐HB (control vaccine)
Number of subjects: 101832
Study 11522460 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 38
Study 11522460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9753212 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (therapeutic doses) with rifabutin 300 mg/day
Number of subjects: 30
Study 9753212 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (therapeutic doses) with rifabutin 300 mg/day
Number of subjects: 30
Study 9753212 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin 300 mg/day alone
Number of subjects: 30
Study 9753212 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin with rifabutin
Number of subjects: 30
Study 7831625 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 8
Study 7831625 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 8
Study 3364811 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 and 0.15 mg.kg‐1 respectively)
Number of subjects: 80
Study 3364811 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (3 and 1.5 mg.kg‐1 respectively)
Number of subjects: 80
Study 29607631 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally-advanced flap along with placental membrane (group II)
Number of subjects: 15
Study 29607631 — intervention group
Group type: COMPARATOR
Intervention: Coronally-advanced flap alone (group I)
Number of subjects: 15
Study 28699554 — intervention group
Group type: EXPERIMENTAL
Intervention: Temephos application in intervention sites
Number of subjects: 10491
Study 28699554 — intervention group
Group type: COMPARATOR
Intervention: Control sites without intervention
Number of subjects: 10491
Study 28699554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clusters
Number of subjects: 10491
Study 28699554 — intervention group
Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 10491
Study 28699554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sites
Number of subjects: 10491
Study 28699554 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 10491
Study 25488056 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae (500 mg once daily for 8 weeks)
Number of subjects: 179
Study 25488056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 23047002 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab
Number of subjects: 1105
Study 23047002 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 1105
Study 23047002 — intervention group
Group type: COMPARATOR
Intervention: ranibizumab or bevacizumab
Number of subjects: 1105
Study 21782352 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (n=15)
Number of subjects: 36
Study 21782352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 36
Study 17943923 — intervention group
Group type: EXPERIMENTAL
Intervention: D-optimal design for complete data
Number of subjects: 0
Study 17943923 — intervention group
Group type: EXPERIMENTAL
Intervention: D-optimal design for data with dropout
Number of subjects: 0
Study 17943923 — intervention group
Group type: EXPERIMENTAL
Intervention: D-optimal design points for the dropout case
Number of subjects: 0
Study 14697066 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedic treatment (IO)
Number of subjects: 20
Study 14697066 — intervention group
Group type: COMPARATOR
Intervention: Non-infant orthopedic treatment (non-IO)
Number of subjects: 20
Study 10667615 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4 (0.5 mg/60 min)
Number of subjects: 28
Study 10667615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10667615 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4
Number of subjects: 28
Study 8567853 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos from patients with PCOS
Number of subjects: 51
Study 8567853 — intervention group
Group type: COMPARATOR
Intervention: Embryos from patients with tubal disease
Number of subjects: 51
Study 8567853 — intervention group
Group type: EXPERIMENTAL
Intervention: Surplus embryos from patients with PCOS
Number of subjects: 51
Study 8567853 — intervention group
Group type: COMPARATOR
Intervention: Surplus embryos from patients with tubal disease
Number of subjects: 51
Study 8567853 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos from patients with anovulatory PCOS
Number of subjects: 51
Study 8567853 — intervention group
Group type: COMPARATOR
Intervention: Embryos from patients with tubal disease with optimized ovulation induction regimen
Number of subjects: 51
Study 1969198 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg itraconazole daily for 3 to 6 months
Number of subjects: 15
Study 1969198 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole daily for 6 to 8 months
Number of subjects: 15
Study 1969198 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole daily for 6 months
Number of subjects: 15
Study 1969198 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg itraconazole daily
Number of subjects: 15
Study 1969198 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up studies
Number of subjects: 15
Study 508557 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0
Study 508557 — intervention group
Group type: COMPARATOR
Intervention: Control (no probenecid)
Number of subjects: 0
Study 30761964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hipcref diet (n 65)
Number of subjects: 128
Study 30761964 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n 63)
Number of subjects: 128
Study 27981752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue intervention (40 contractions at 55%MVFb)
Number of subjects: 11
Study 27981752 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (40 contractions at 5%MVFb)
Number of subjects: 11
Study 25715865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 893
Study 25715865 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lorazepam
Number of subjects: 893
Study 24378762 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured hypocaloric diet (n = 63); energy restriction (−300 to −500 kcal/d) emphasizing cardioprotective dietary changes
Number of subjects: 118
Study 24378762 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapy (BT) (n = 55); goal setting, problem-solving, and stimulus control
Number of subjects: 118
Study 23134211 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg/day
Number of subjects: 226
Study 23134211 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 226
Study 19670053 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone case management over a 12 month period
Number of subjects: 99
Study 17561794 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Start DVD presentation and a 30‐min diet education course (SS Group)
Number of subjects: 30
Study 17561794 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 30
Study 15047649 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser therapy (LILT)
Number of subjects: 50
Study 15047649 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 50
Study 11496809 — intervention group
Group type: EXPERIMENTAL
Intervention: Enuresis alarm treatment
Number of subjects: 22
Study 11496809 — intervention group
Group type: COMPARATOR
Intervention: Different types of enuresis alarms
Number of subjects: 22
Study 9602874 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (20 micrograms per wound)
Number of subjects: 10
Study 9602874 — intervention group
Group type: COMPARATOR
Intervention: Solvent control
Number of subjects: 10
Study 7747584 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthesia (group A)
Number of subjects: 0
Study 7747584 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival anaesthesia (group B)
Number of subjects: 0
Study 2557881 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60‐75 mg m‐2 intravenously once every 3 weeks
Number of subjects: 75
Study 2557881 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2 interferon (rIFN) 9‐18 x 10(6) IU m‐2 intramuscularly daily
Number of subjects: 75
Study 2557881 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2 interferon (rIFN) 25‐50 x 10(6) IU m‐2 intramuscularly three times weekly
Number of subjects: 75
Study 31493631 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset bipolar disorder (EOBD)
Number of subjects: 64854
Study 31493631 — intervention group
Group type: COMPARATOR
Intervention: Adult-onset bipolar disorder (AOBD)
Number of subjects: 64854
Study 31493631 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-controlled comparison subjects without bipolar disorder)
Number of subjects: 64854
Study 31046481 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 inhibitors
Number of subjects: 0
Study 31046481 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-23/p19 inhibitors
Number of subjects: 0
Study 31046481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study 31046481 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 0
Study 31046481 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 0
Study 27812798 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 4
Study 27812798 — intervention group
Group type: EXPERIMENTAL
Intervention: Web app
Number of subjects: 4
Study 25880034 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma-acupressure
Number of subjects: 186
Study 25880034 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 186
Study 25880034 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 186
Study 23993130 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg once daily
Number of subjects: 1156
Study 23993130 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 400mg twice daily plus Metronidazole 500mg twice daily
Number of subjects: 1156
Study 21898711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast left repetitive transcranial magnetic stimulation (rTMS) at 10 Hz @ 120% of motor threshold (MT) over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 141
Study 21898711 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow right rTMS at 1 Hz @ 120% MT over the right DLPFC
Number of subjects: 141
Study 19376589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg bevacizumab
Number of subjects: 42
Study 19376589 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery only (control)
Number of subjects: 42
Study 17326710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia induced by insulin infusion to nadir levels of 2.2 mmol/l
Number of subjects: 32
Study 17326710 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia maintained (control)
Number of subjects: 32
Study 17326710 — intervention group
Group type: EXPERIMENTAL
Intervention: Awakening during hypoglycemia
Number of subjects: 32
Study 17326710 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in epinephrine
Number of subjects: 32
Study 15381895 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg
Number of subjects: 44
Study 15381895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12364470 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH (0.05 mg/kg.d)
Number of subjects: 198
Study 12364470 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GH (0.025 mg/kg.d)
Number of subjects: 198
Study 12364470 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH-IGFBP-3 generation test
Number of subjects: 198
Study 9845100 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiation therapy with mitomycin C (V‐CHART + MMC)
Number of subjects: 188
Study 9845100 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiation therapy (V‐CHART)
Number of subjects: 188
Study 9845100 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 188
Study 7978438 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (transdermal 0.2 mg/d for 72 h + oral 0.3 mg 60‐90 min before surgery)
Number of subjects: 61
Study 7978438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 2729850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 42
Study 2729850 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (Control)
Number of subjects: 42
Study 31883356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 1100
Study 31883356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study 27445067 — intervention group
Group type: EXPERIMENTAL
Intervention: HA‐trehalose (n = 52)
Number of subjects: 105
Study 27445067 — intervention group
Group type: COMPARATOR
Intervention: HA (n = 53)
Number of subjects: 105
Study 24246711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 249
Study 24246711 — intervention group
Group type: COMPARATOR
Intervention: Conventional in vitro fertilization (IVF)
Number of subjects: 249
Study 23290005 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (8-week program)
Number of subjects: 28
Study 23290005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 21703665 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel emission control law enforcement (April 2006 to December 2008)
Number of subjects: 0
Study 21703665 — intervention group
Group type: COMPARATOR
Intervention: Pre-enforcement period (April 2003 to March 2006)
Number of subjects: 0
Study 21703665 — intervention group
Group type: EXPERIMENTAL
Intervention: High traffic areas post-enforcement
Number of subjects: 0
Study 21703665 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude interrupted time-series analysis
Number of subjects: 0
Study 17631296 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar (0.1, 0.25, 0.5, and 1mg) once daily for 12 weeks
Number of subjects: 390